Molecular Imaging of Alzheimer Disease Pathology

References

1. 1.↵
   1. Klunk WE,
   2. Engler H,
   3. Nordberg A,
   4. et al

   . Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004;55:306–19

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Pike KE,
   2. Ellis KA,
   3. Villemagne VL,
   4. et al

   . Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. Neuropsychologia 2011;49:2384–90

   CrossRefPubMed
3. 3.↵
   1. Morris JC,
   2. Roe CM,
   3. Xiong C,
   4. et al

   . APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67:122–31

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Aizenstein HJ,
   2. Nebes RD,
   3. Saxton JA,
   4. et al

   . Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008;65:1509–17

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Kantarci K,
   2. Lowe V,
   3. Przybelski SA,
   4. et al

   . APOE modifies the association between Abeta load and cognition in cognitively normal older adults. Neurology 2012;78:232–40

   CrossRef
6. 6.↵
   1. Landau SM,
   2. Mintun MA,
   3. Joshi AD,
   4. et al

   . Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012;72:578–86

   CrossRefPubMed
7. 7.↵
   1. Mielke MM,
   2. Wiste HJ,
   3. Weigand SD,
   4. et al

   . Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology 2012;79:1570–77

   CrossRef
8. 8.↵
   1. Sonnen JA,
   2. Larson EB,
   3. Crane PK,
   4. et al

   . Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol 2007;62:406–13

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Pike KE,
   2. Savage G,
   3. Villemagne VL,
   4. et al

   . Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007;130:2837–44

   Abstract/FREE Full Text
10. 10.↵
    1. Chételat G,
    2. Villemagne VL,
    3. Pike KE,
    4. et al

    . Relationship between memory performance and beta-amyloid deposition at different stages of Alzheimer's disease. Neurodegener Dis 2012;10:141–44

    CrossRefPubMed
11. 11.↵
    1. Fagan AM,
    2. Mintun MA,
    3. Shah AR,
    4. et al

    . Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 2009;1:371–80

    Abstract/FREE Full Text
12. 12.↵
    1. Mormino EC,
    2. Kluth JT,
    3. Madison CM,
    4. et al

    . Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009;132:1310–23

    Abstract/FREE Full Text
13. 13.↵
    1. Doraiswamy PM,
    2. Sperling RA,
    3. Coleman RE,
    4. et al

    . Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 2012;79:1636–44

    CrossRef
14. 14.↵
    1. Chételat G,
    2. Villemagne VL,
    3. Pike KE,
    4. et al

    . Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Brain 2011;134:798–807

    Abstract/FREE Full Text
15. 15.↵
    1. Rentz DM,
    2. Amariglio RE,
    3. Becker JA,
    4. et al

    . Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia 2011;49:2776–83

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Rodrigue KM,
    2. Kennedy KM,
    3. Devous MD Sr.,
    4. et al

    . Beta-amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology 2012;78:387–95

    CrossRefPubMed
17. 17.↵
    1. Sperling RA,
    2. Johnson KA,
    3. Doraiswamy PM,
    4. et al

    . Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging 2013;34:822–31

    CrossRefPubMed
18. 18.↵
    1. Hedden T,
    2. Oh H,
    3. Younger AP,
    4. et al

    . Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology 2013;80:1341–48

    CrossRefPubMed
19. 19.↵
    1. Lim YY,
    2. Ellis KA,
    3. Ames D,
    4. et al

    . Abeta amyloid, cognition, and APOE genotype in healthy older adults. Alzheimers Dement 2013;9:538–45

    CrossRefPubMed
20. 20.↵
    1. Fleisher AS,
    2. Chen K,
    3. Liu X,
    4. et al

    . Apolipoprotein E epsilon4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging 2013;34:1–12

    CrossRefPubMed
21. 21.↵
    1. Ledesma MD,
    2. Medina M,
    3. Avila J

    . The in vitro formation of recombinant tau polymers: effect of phosphorylation and glycation. Mol Chem Neuropathol 1996;27:249–58

    CrossRefPubMed
22. 22.↵
    1. Dubelaar EJ,
    2. Verwer RW,
    3. Hofman MA,
    4. et al

    . ApoE epsilon4 genotype is accompanied by lower metabolic activity in nucleus basalis of Meynert neurons in Alzheimer patients and controls as indicated by the size of the Golgi apparatus. J Neuropathol Exp Neurol 2004;63:159–69

    PubMedWeb of Science
23. 23.↵
    1. Jack CR Jr.,
    2. Albert MS,
    3. Knopman DS,
    4. et al

    . Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:257–62

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Sperling RA,
    2. Aisen PS,
    3. Beckett LA,
    4. et al

    . Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280–92

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Roberts RO,
    2. Geda YE,
    3. Knopman DS,
    4. et al

    . The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008;30:58–69

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Jack CR Jr.,
    2. Knopman DS,
    3. Weigand SD,
    4. et al

    . An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 2012;71:765–75

    CrossRefPubMed
27. 27.↵
    1. Knopman DS,
    2. Jack CR Jr.,
    3. Wiste HJ,
    4. et al

    . Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012;78:1576–82

    CrossRefPubMed
28. 28.↵
    1. Knopman DS,
    2. Jack CR Jr..,
    3. Wiste HJ,
    4. et al

    . Brain injury biomarkers are not dependent on beta-amyloid in normal elderly. Ann Neurol 2012 Nov 23. [Epub ahead of print]
29. 29.↵
    1. Petersen RC,
    2. Aisen P,
    3. Boeve BF,
    4. et al

    . Criteria for mild cognitive impairment due to Alzheimer's disease in the community. Ann Neurol 2013 May 20. [Epub ahead of print]
30. 30.↵
    1. Mosconi L,
    2. Andrews RD,
    3. Matthews DC

    . Comparing brain amyloid deposition, glucose metabolism, and atrophy in mild cognitive impairment with and without a family history of dementia. J Alzheimers Dis 2013;35:509–24

    PubMed
31. 31.↵
    1. Vemuri P,
    2. Lesnick TG,
    3. Przybelski SA,
    4. et al

    . Effect of lifestyle activities on Alzheimer disease biomarkers and cognition. Ann Neurol 2012;72:730–38

    CrossRefPubMed
32. 32.↵
    1. Kemppainen NM,
    2. Aalto S,
    3. Karrasch M,
    4. et al

    . Cognitive reserve hypothesis: Pittsburgh compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol 2008;63:112–18

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Mathis CA,
    2. Wang Y,
    3. Holt DP,
    4. et al

    . Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740–54

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Manook A,
    2. Yousefi BH,
    3. Willuweit A,
    4. et al

    . Small-animal PET imaging of amyloid-beta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease. PLoS One 2012;7:e31310

    CrossRefPubMed
35. 35.↵
    1. Ikonomovic MD,
    2. Klunk WE,
    3. Abrahamson EE,
    4. et al

    . Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131:1630–45

    Abstract/FREE Full Text
36. 36.↵
    1. Choi SR,
    2. Schneider JA,
    3. Bennett DA,
    4. et al

    . Correlation of amyloid PET ligand florbetapir F 18 binding with Abeta aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord 2012;26:8–16

    CrossRefPubMed
37. 37.↵
    1. Lin KJ,
    2. Hsu WC,
    3. Hsiao IT,
    4. et al

    . Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent–a pilot study. Nucl Med Biol 2010;37:497–508

    CrossRefPubMedWeb of Science
38. 38.↵
    1. Wong DF,
    2. Rosenberg PB,
    3. Zhou Y,
    4. et al

    . In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 2010;51:913–20

    Abstract/FREE Full Text
39. 39.↵
    1. Poisnel G,
    2. Dhilly M,
    3. Moustie O,
    4. et al

    . PET imaging with [18F]AV-45 in an APP/PS1–21 murine model of amyloid plaque deposition. Neurobiol Aging 2012;33:2561–71

    CrossRefPubMed
40. 40.↵
    1. Cselényi Z,
    2. Jonhagen ME,
    3. Forsberg A,
    4. et al

    . Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioligand. J Nucl Med 2012;53:415–24

    Abstract/FREE Full Text
41. 41.↵
    1. Rowe CC,
    2. Pejoska S,
    3. Mulligan RS,
    4. et al

    . Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia. J Nucl Med 2013;54:880–86

    Abstract/FREE Full Text
42. 42.↵
    1. Villemagne VL,
    2. Mulligan RS,
    3. Pejoska S,
    4. et al

    . Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012;39:983–89

    CrossRefPubMed
43. 43.↵
    1. Wolk DA,
    2. Zhang Z,
    3. Boudhar S,
    4. et al

    . Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry 2012;83:923–26

    Abstract/FREE Full Text
44. 44.↵
    1. Becker GA,
    2. Ichise M,
    3. Barthel H,
    4. et al

    . PET quantification of 18F-florbetaben binding to beta-amyloid deposits in human brains. J Nucl Med 2013;54:723–31

    Abstract/FREE Full Text
45. 45.↵
    1. Landau SM,
    2. Breault C,
    3. Joshi AD,
    4. et al

    . Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med 2013;54:70–77

    Abstract/FREE Full Text
46. 46.↵
    1. Burack MA,
    2. Hartlein J,
    3. Flores HP,
    4. et al

    . In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010;74:77–84

    CrossRef
47. 47.↵
    1. Kantarci K,
    2. Yang C,
    3. Schneider JA,
    4. et al

    . Antemortem amyloid imaging and beta-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging 2012;33:878–85

    CrossRefPubMedWeb of Science
48. 48.↵
    1. Fodero-Tavoletti MT,
    2. Smith DP,
    3. McLean CA,
    4. et al

    . In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci 2007;27:10365–71

    Abstract/FREE Full Text
49. 49.↵
    1. Ye L,
    2. Velasco A,
    3. Fraser G,
    4. et al

    . In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem 2008;105:1428–37

    CrossRefPubMedWeb of Science
50. 50.↵
    1. Lockhart A,
    2. Lamb JR,
    3. Osredkar T,
    4. et al

    . PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 2007;130:2607–15

    Abstract/FREE Full Text
51. 51.↵
    1. Ikonomovic MD,
    2. Abrahamson EE,
    3. Price JC,
    4. et al

    . Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathol 2012;123:433–47

    CrossRefPubMedWeb of Science
52. 52.↵
    1. Clark CM,
    2. Schneider JA,
    3. Bedell BJ,
    4. et al

    . Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011;305:275–83

    CrossRefPubMedWeb of Science
53. 53.↵
    1. Sojkova J,
    2. Driscoll I,
    3. Iacono D,
    4. et al

    . In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol 2011;68:232–40

    CrossRefPubMedWeb of Science
54. 54.↵
    1. Kantarci K,
    2. Lowe VJ,
    3. Boeve BF,
    4. et al

    . Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging 2012;33:2091–105

    CrossRefPubMed
55. 55.↵
    1. Villemagne VL,
    2. Ong K,
    3. Mulligan RS,
    4. et al

    . Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 2011;52:1210–17

    Abstract/FREE Full Text
56. 56.↵
    1. Rabinovici GD,
    2. Rosen HJ,
    3. Alkalay A,
    4. et al

    . Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 2011;77:2034–42

    CrossRef
57. 57.↵
    1. Schneider JA,
    2. Arvanitakis Z,
    3. Bang W,
    4. et al

    . Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007;69:2197–204

    CrossRef
58. 58.↵
    1. Sonnen JA,
    2. Santa Cruz K,
    3. Hemmy LS,
    4. et al

    . Ecology of the aging human brain. Arch Neurol 2011;68:1049–56

    CrossRefPubMedWeb of Science
59. 59.↵
    1. Edison P,
    2. Rowe CC,
    3. Rinne JO,
    4. et al

    . Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008;79:1331–38

    Abstract/FREE Full Text
60. 60.↵
    1. Foster ER,
    2. Campbell MC,
    3. Burack MA,
    4. et al

    . Amyloid imaging of Lewy body-associated disorders. Mov Disord 2010;25:2516–23

    CrossRefPubMed
61. 61.↵
    1. Gomperts SN,
    2. Rentz DM,
    3. Moran E,
    4. et al

    . Imaging amyloid deposition in Lewy body diseases. Neurology 2008;71:903–10

    CrossRef
62. 62.↵
    1. Maetzler W,
    2. Liepelt I,
    3. Reimold M,
    4. et al

    . Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 2009;34:107–12

    CrossRefPubMedWeb of Science
63. 63.↵
    1. Kantarci K,
    2. Ferman TJ,
    3. Boeve BF,
    4. et al

    . Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology 2012;79:553–60

    CrossRef
64. 64.↵
    1. O'Brien JT,
    2. Colloby S,
    3. Fenwick J,
    4. et al

    . Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919–25

    CrossRefPubMedWeb of Science
65. 65.↵
    1. Villemagne VL,
    2. Okamura N,
    3. Pejoska S,
    4. et al

    . Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imaging. Neurodegener Dis 2012;10:161–65

    CrossRefPubMed
66. 66.↵
    1. Camus V,
    2. Payoux P,
    3. Barre L,
    4. et al

    . Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging 2012;39:621–31

    CrossRefPubMed
67. 67.↵
    1. Frederiksen KS,
    2. Hasselbalch SG,
    3. Hejl AM,
    4. et al

    . Added diagnostic value of (11)C-PiB-PET in memory clinic patients with uncertain diagnosis. Dement Geriatr Cogn Dis Extra 2012;2:610–21

    CrossRefPubMed
68. 68.↵
    1. Ossenkoppele R,
    2. Prins ND,
    3. Pijnenburg YA,
    4. et al

    . Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement 2013;9:414–21

    CrossRefPubMed
69. 69.↵
    1. Frisoni GB,
    2. Bocchetta M,
    3. Chetelat G,
    4. et al

    . Imaging markers for Alzheimer disease: which vs how. Neurology 2013;81:487–500

    CrossRef
70. 70.↵
    1. Mitka M

    . PET imaging for Alzheimer disease: are its benefits worth the cost? JAMA 2013;309:1099–100

    CrossRefPubMedWeb of Science
71. 71.↵
    1. Jack CR Jr.,
    2. Knopman DS,
    3. Jagust WJ,
    4. et al

    . Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119–28

    CrossRefPubMedWeb of Science
72. 72.↵
    1. Jack CR Jr.,
    2. Knopman DS,
    3. Jagust WJ,
    4. et al

    . Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207–16

    CrossRefPubMedWeb of Science
73. 73.↵
    1. Jack CR Jr.,
    2. Wiste HJ,
    3. Lesnick TG,
    4. et al

    . Brain beta-amyloid load approaches a plateau. Neurology 2013;80:890–96

    CrossRef
74. 74.↵
    1. Villemagne VL,
    2. Burnham S,
    3. Bourgeat P,
    4. et al

    . Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013;12:357–67

    CrossRefPubMedWeb of Science
75. 75.↵
    1. Kadir A,
    2. Almkvist O,
    3. Forsberg A,
    4. et al

    . Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging 2012;33:198.e1–14

    CrossRefPubMed
76. 76.↵
    1. Koivunen J,
    2. Scheinin N,
    3. Virta JR,
    4. et al

    . Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology 2011;76:1085–90

    CrossRef
77. 77.↵
    1. Ossenkoppele R,
    2. Tolboom N,
    3. Foster-Dingley JC,
    4. et al

    . Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. Eur J Nucl Med Mol Imaging 2012;39:990–1000

    CrossRefPubMed
78. 78.↵
    1. Sojkova J,
    2. Zhou Y,
    3. An Y,
    4. et al

    . Longitudinal patterns of beta-amyloid deposition in nondemented older adults. Arch Neurol 2011;68:644–49

    CrossRefPubMedWeb of Science
79. 79.↵
    1. Villemagne VL,
    2. Pike KE,
    3. Chetelat G,
    4. et al

    . Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011;69:181–92

    CrossRefPubMedWeb of Science
80. 80.↵
    1. Villain N,
    2. Chetelat G,
    3. Grassiot B,
    4. et al

    . Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain 2012;135:2126–39

    Abstract/FREE Full Text
81. 81.↵
    1. Jack CR Jr.,
    2. Lowe VJ,
    3. Weigand SD,
    4. et al

    . Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355–65

    Abstract/FREE Full Text
82. 82.↵
    1. Bateman RJ,
    2. Xiong C,
    3. Benzinger TL,
    4. et al

    . Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795–804

    CrossRefPubMedWeb of Science
83. 83.↵
    1. Fleisher AS,
    2. Chen K,
    3. Quiroz YT,
    4. et al

    . Florbetapir PET analysis of amyloid-beta deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol 2012;11:1057–65

    CrossRefPubMedWeb of Science
84. 84.↵
    1. Sperling RA,
    2. Jack CR Jr.,
    3. Aisen PS

    . Testing the right target and right drug at the right stage. Sci Transl Med 2011;3:111cm33

    FREE Full Text
85. 85.↵
    1. Barthel H,
    2. Luthardt J,
    3. Becker G,
    4. et al

    . Individualized quantification of brain beta-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. Eur J Nucl Med Mol Imaging 2011;38:1702–14

    CrossRefPubMed
86. 86.↵
    1. Rinne JO,
    2. Brooks DJ,
    3. Rossor MN,
    4. et al

    . 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363–72

    CrossRefPubMedWeb of Science
87. 87.↵
    1. Small GW,
    2. Siddarth P,
    3. Kepe V,
    4. et al

    . Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. Arch Neurol 2012;69:215–22

    CrossRefPubMedWeb of Science
88. 88.↵
    1. Small GW,
    2. Kepe V,
    3. Ercoli LM,
    4. et al

    . PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006;355:2652–63

    CrossRefPubMedWeb of Science
89. 89.↵
    1. Okamura N,
    2. Furumoto S,
    3. Harada R,
    4. et al

    . Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer eisease. J Nucl Med 2013;54:1420–27

    Abstract/FREE Full Text
90. 90.↵
    1. Petersen RC

    . Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183–94

    CrossRefPubMedWeb of Science